期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 44, 期 12, 页码 1028-1042出版社
CELL PRESS
DOI: 10.1016/j.tips.2023.10.002
关键词
-
Immunological tolerance is crucial in addressing the immunogenicity of therapeutic proteins. Traditional approaches are inefficient and expensive, but recent studies have shown promising results with emerging technologies. Overcoming barriers is still necessary for translation into the clinic.
Immunogenicity affects the safety and efficacy of therapeutic proteins. This review is focused on approaches for inducing immunological tolerance to circumvent the immunogenicity of therapeutic proteins in the clinic. The few immune tolerance strategies that are used in the clinic tend to be inefficient and expensive and typically involve global immunosuppression, putting patients at risk of infections. The hallmark of a desirable immune tolerance regimen is the specific alleviation of immune responses to the therapeutic protein. In the past decade, proof-of-principle studies have demonstrated that emerging technologies, including nanoparticle-based delivery of immunomodulators, cellular targeting and depletion, cellular engineering, gene therapy, and gene editing, can be leveraged to promote tolerance to therapeutic proteins. We discuss the potential of these novel approaches and the barriers that need to be overcome for translation into the clinic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据